Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Bought by State of Alaska Department of Revenue

State of Alaska Department of Revenue increased its stake in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 79.5% during the second quarter, according to its most recent filing with the SEC. The institutional investor owned 9,929 shares of the specialty pharmaceutical company’s stock after buying an additional 4,399 shares during the period. State of Alaska Department of Revenue’s holdings in Supernus Pharmaceuticals were worth $427,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Ameritas Investment Partners Inc. bought a new position in Supernus Pharmaceuticals during the first quarter valued at $127,000. Fortaleza Asset Management Inc. bought a new position in Supernus Pharmaceuticals during the first quarter valued at $160,000. OppenheimerFunds Inc. bought a new position in Supernus Pharmaceuticals during the first quarter valued at $205,000. First Citizens Bank & Trust Co. bought a new position in Supernus Pharmaceuticals during the first quarter valued at $208,000. Finally, Turner Investments LLC bought a new position in Supernus Pharmaceuticals during the first quarter valued at $219,000. 94.39% of the stock is currently owned by hedge funds and other institutional investors.

Supernus Pharmaceuticals, Inc. (NASDAQ SUPN) opened at 41.40 on Friday. The company has a 50-day moving average of $42.47 and a 200-day moving average of $34.12. Supernus Pharmaceuticals, Inc. has a 52 week low of $17.25 and a 52 week high of $44.95. The company has a market capitalization of $2.10 billion, a PE ratio of 20.89 and a beta of 1.31.

Supernus Pharmaceuticals (NASDAQ:SUPN) last announced its quarterly earnings results on Wednesday, August 2nd. The specialty pharmaceutical company reported $0.32 EPS for the quarter, beating the Zacks’ consensus estimate of $0.24 by $0.08. The company had revenue of $75.83 million for the quarter, compared to analysts’ expectations of $68.54 million. Supernus Pharmaceuticals had a net margin of 41.10% and a return on equity of 30.73%. On average, equities research analysts anticipate that Supernus Pharmaceuticals, Inc. will post $1.04 EPS for the current year.

COPYRIGHT VIOLATION NOTICE: This piece was originally published by Community Financial News and is the property of of Community Financial News. If you are reading this piece on another publication, it was copied illegally and republished in violation of U.S. & international copyright & trademark laws. The correct version of this piece can be viewed at https://www.com-unik.info/2017/08/12/state-of-alaska-department-of-revenue-raises-stake-in-supernus-pharmaceuticals-inc-nasdaqsupn-updated-updated.html.

Several research analysts have weighed in on the stock. BidaskClub cut shares of Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, August 2nd. Jefferies Group LLC reaffirmed a “buy” rating and set a $51.00 target price on shares of Supernus Pharmaceuticals in a report on Friday, August 4th. Janney Montgomery Scott assumed coverage on shares of Supernus Pharmaceuticals in a report on Friday, July 14th. They set a “neutral” rating and a $47.00 target price on the stock. Cowen and Company reaffirmed a “positive” rating and set a $50.00 target price (up from $40.00) on shares of Supernus Pharmaceuticals in a report on Thursday, August 3rd. Finally, Stifel Nicolaus reaffirmed a “buy” rating and set a $47.00 target price (up from $36.00) on shares of Supernus Pharmaceuticals in a report on Tuesday, July 18th. Four analysts have rated the stock with a hold rating and four have given a buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $48.43.

In related news, VP Padmanabh P. Bhatt sold 3,735 shares of the company’s stock in a transaction that occurred on Wednesday, July 12th. The shares were sold at an average price of $44.90, for a total transaction of $167,701.50. Following the sale, the vice president now owns 21,209 shares of the company’s stock, valued at approximately $952,284.10. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Padmanabh P. Bhatt sold 2,500 shares of the company’s stock in a transaction that occurred on Friday, May 26th. The stock was sold at an average price of $35.90, for a total transaction of $89,750.00. Following the sale, the vice president now directly owns 37,500 shares in the company, valued at approximately $1,346,250. The disclosure for this sale can be found here. Insiders have sold a total of 24,291 shares of company stock worth $962,766 in the last ninety days. 6.70% of the stock is currently owned by insiders.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.

Institutional Ownership by Quarter for Supernus Pharmaceuticals (NASDAQ:SUPN)

What are top analysts saying about Supernus Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Supernus Pharmaceuticals Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit